1 January 2022 in American Journal of Ophthalmology
To analyze the relationship between rates of false positive (FP) responses and standard automated perimetry results. Prospective multicenter cross-sectional study. One hundred twenty-six patients with manifest or suspect glaucoma were tested with Swedish Interactive Thresholding Algorithm (SITA) Standard, SITA Fast, and SITA Faster at each of 2 visits. We calculated intervisit differences in mean deviation (MD), visual field index (VFI), and number of statistically significant test points as a function of FP rates and also as a function of general height (GH). Increasing FP values were associated with higher MD values for all 3 algorithms, but the effects were small, 0.3 dB to 0.6 dB, for an increase of 10 percentage points of FP rate, and for VFI even smaller (0.6%-1.4%). Only small parts of intervisit differences were explained by FP (r2 values 0.00-0.11). The effects of FP were larger in severe glaucoma, with MD increases of 1.1 dB to 2.0 dB per 10 percentage points of FP, and r2 values ranging from 0.04 to 0.33. The numbers of significantly depressed total deviation points were affected only slightly, and pattern deviation probability maps were generally unaffected. GH was much more strongly related to perimetric outcomes than FP. Across 3 different standard automated perimetry thresholding algorithms, FP rates showed only weak associations with visual field test results, except in severe glaucoma. Current recommendations regarding acceptable FP ranges may require revision. GH or other analyses may be better suited than FP rates for identifying unreliable results in patients who frequently press the response button without having perceived stimuli.
24 November 2009 in Acta Ophthalmologica
: Purpose: The aims of this study were: (i) to create a structural simulation model capable of predicting the future need and cost of eyecare services in Finland; and (ii) to test and rank different policy alternatives for access to care and the required physician workforce.Methods: Using the system dynamics approach, the number and cost of patients with cataract, glaucoma, diabetic retinopathy and age‐related macular degeneration (AMD) were described with causal‐loop diagrams and were then translated into a set of mathematical equations to build a computer simulation model. Mathematically, the problem was formulated as a set of differential equations that were solved numerically with specialized software. The validity of the model was tested against prevalence and administrative historical data. The costs covered by the public sector in Finland were obtained from 2003 from the Finnish Hospital Discharge Register (including outpatient care), the Finnish Social Insurance Institution and a survey of hospital price lists. Different levels of access to public care were then simulated in four eye diseases, for which the model estimated the need for services and resources and their costs in the years 2005–2040.Results: The model forecasted that the adoption of the 2005 national ‘access to care’ criteria for cataract surgery would shorten waiting lists. If the workload of Finnish ophthalmologists were kept at the 2003 level, the graduation rate of new ophthalmologists would have to increase by 75% from the current level. If all glaucoma patients were followed in the public sector in future, even this increase in training would not meet the demand for physician workforce. The current model indicated that the screening frequency of diabetes can be increased without large sacrifices in terms of costs. AMD therapy has a significant role in the allocation of future resources in eyecare. The modelling study predicted that ageing alone will increase the costs of eyecare during the next four decades in Finland by about 1% per year in real terms (undiscounted and without inflation of unit costs). The increases in total yearly costs were on average 8.6% between 2001 and 2003.Conclusions: The results of this modelling study indicate that policy initiatives, such as defining criteria for access to care, can have substantial implications on the demand for care and waiting times whereas the effect of ageing alone was relatively small. Measures to control several other factors – such as the adoption and price level of new technologies, treatments and practice patterns – will be at least equally important in order to restrain healthcare costs effectively.
1 January 2011 in Indian Journal Of Ophthalmology
As all developed countries are struggling with health care costs growing too large and too fast, the current performance and overburden of glaucoma services demand a reappraisal of current management strategies. The performance of the glaucoma care in western countries offers several opportunities to improve the simultaneous under- and over-diagnosis and treatment. Since available resources are finite, they should be targeted to produce the best eye health. There is an obvious need for prioritization of all interventions, including improving case finding. The limited evidence to date indicates that we do not have enough evidence to decide whether systematic population screening could be cost-effective in the developed world. This article gives an overview of the methods of economic evaluation and the evidence on cost-effectiveness of systematic screening for glaucoma in the developed world, need for future research and challenges related to evaluation of increasing economic literature as well as need to change behaviors on the basis of evidence.
16 July 2016 in Acta Ophthalmologica
8 October 2013 in BMC Ophthalmology
To describe the rationale and design of the Northern Finland Birth Cohort (NFBC) Eye Study.
1 March 2011 in Current Opinion in Ophthalmology
This review evaluates the last 18-month literature related to costs and glaucoma. The emphasis is to look at evidence as a big picture and evaluate the critical points and challenges in methodology, current knowledge and future research. On the basis of simulation models, treating glaucoma appears to be cost-effective compared with no treatment. The results of the simulation models are, however, not consistent regarding when to treat ocular hypertension and when comparing different therapeutic interventions. Most models simulated starting treatment with prostaglandins compared with other medications, whereas one study simulated also initial laser therapy which appeared to be cost saving compared with medical therapy. The models utilized input data both from randomized controlled trials (ideal outcomes) and observational studies (with incomplete and selective reporting). Models suffer from unreliability of data, for example data from randomized diagnostic trials, empirical data of utility values and glaucoma-induced visual disability are limited. As the number of economic evaluations increases, the interpretation and evaluation of their extensive reporting appears very challenging. The published studies highlight the range of uncertainties due to the shortages of our current knowledge and evidence. There is a need for reliable and 'realistic' data for economic evaluations, preferably data from pragmatic randomized trials of 'usual patients'. Similar to emphasizing the cost-effectiveness of care, there is a need to evaluate the expected payback and cost-effectiveness of research interventions. However, even high-quality evidence cannot help our patients if we do not adopt cost-effective interventions.